{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:24:03Z","timestamp":1789687443563,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Large randomized controlled trials (RCTs) have reported data on neoadjuvant therapies for locally advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, no clear recommendation is provided regarding the optimal choice of neoadjuvant regimen. This network meta-analysis (NMA) endeavors to identify the best neoadjuvant therapy for the locally advanced GC and GEJC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Cochrane Library, and Web of Science databases were searched systematically until September 6, 2024 and update until November 14, 2025. This study encompassed RCTs investigating neoadjuvant treatment for locally advanced GC or GEJC that reported outcomes on overall survival (OS), pathological complete response (pCR), as well as R0 resection rates. Study quality was rated utilizing the Cochrane Risk of Bias Tool 2.0. Bayesian network meta-analysis (BNMA) was conducted through Stata and RStudio for efficacy comparison and ranking of all regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>26 RCTs comprising 7,324 patients with GC or GEJC were encompassed. Through the surface under the cumulative ranking curve (SUCRA), DOX ranked highest for OS. FLOT combined with Durvalumab (FLOT_Durvalumab) demonstrated a superior pCR rate, while DOS combined with apatinib (DOS_Apatinib) ranked highest for R0 resection rate. DOX significantly prolonged OS compared with CS (HR\u2009=\u20090.54, 95% CrI: 0.29\u20130.99), surgery (HR\u2009=\u20090.49, 95% CrI: 0.29\u20130.84), and XELOX (HR\u2009=\u20090.59, 95% CrI: 0.35\u20130.99).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DOX appears to be the most effective neoadjuvant treatment for ameliorating OS in patients with GC or GEJC. FLOT_Durvalumab was associated with the highest pCR rate, while DOS_Apatinib appears most effective in achieving R0 resection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-025-04151-z","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:23:59Z","timestamp":1766535839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimal neoadjuvant regimens for locally advanced gastric and gastroesophageal junction cancer: a systematic review and bayesian network meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Wei-Qiang","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ran","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"4151_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Cancer J Clin"},{"key":"4151_CR2","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/s0140-6736(16)30354-3","volume":"388","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet (London England). 2016;388:2654\u201364. https:\/\/doi.org\/10.1016\/s0140-6736(16)30354-3.","journal-title":"Lancet (London England)"},{"key":"4151_CR3","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/jco.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2011;29:1715\u201321. https:\/\/doi.org\/10.1200\/jco.2010.33.0597.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4151_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"},{"key":"4151_CR5","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"key":"4151_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090\u20138. https:\/\/doi.org\/10.1016\/s1470-2045(15)00040-6.","journal-title":"Lancet Oncol"},{"key":"4151_CR7","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384. https:\/\/doi.org\/10.1056\/NEJMoa1112088.","journal-title":"N Engl J Med"},{"key":"4151_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/jco.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch Repair\/Microsatellite Instability-High gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41:255\u201365. https:\/\/doi.org\/10.1200\/jco.22.00686.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4151_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.6004\/jnccn.2022.7023","volume":"20","author":"L Liu","year":"2022","unstructured":"Liu L, et al. Immunotherapy-Based neoadjuvant treatment of advanced microsatellite Instability-High gastric cancer: A case series. J Natl Compr Cancer Network: JNCCN. 2022;20:857\u201365. https:\/\/doi.org\/10.6004\/jnccn.2022.7023.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"4151_CR10","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/jco.22.01351","volume":"41","author":"K Ludford","year":"2023","unstructured":"Ludford K, et al. Neoadjuvant pembrolizumab in localized microsatellite instability High\/Deficient mismatch repair solid tumors. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41:2181\u201390. https:\/\/doi.org\/10.1200\/jco.22.01351.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4151_CR11","doi-asserted-by":"publisher","unstructured":"Raimondi A, et al. TremelImumab and durvalumab combination for the Non-OperatIve management (NOM) of microsatellite instability (MSI)-High resectable gastric or gastroesophageal junction cancer: the Multicentre, Single-Arm, Multi-Cohort, phase II INFINITY study. Cancers. 2021;13. https:\/\/doi.org\/10.3390\/cancers13112839.","DOI":"10.3390\/cancers13112839"},{"key":"4151_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25:212\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7.","journal-title":"Lancet Oncol"},{"key":"4151_CR13","doi-asserted-by":"publisher","unstructured":"Yuan SQ, et al. Perioperative Toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat Med. 2024;30. https:\/\/doi.org\/10.1038\/s41591-023-02721-w.","DOI":"10.1038\/s41591-023-02721-w"},{"key":"4151_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen S, et al. Perioperative Atezolizumab plus Fluorouracil, Leucovorin, Oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the Randomized, Multicenter, phase II\/III DANTE\/IKF-s633 trial. J Clin Oncol. 2024;42:410\u201320. https:\/\/doi.org\/10.1200\/JCO.23.00975.","journal-title":"J Clin Oncol"},{"key":"4151_CR15","doi-asserted-by":"publisher","first-page":"1339757","DOI":"10.3389\/fimmu.2024.1339757","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, et al. Evaluation of neoadjuvant immunotherapy in resectable gastric\/gastroesophageal junction tumors: a meta-analysis and systematic review. Front Immunol. 2024;15:1339757. https:\/\/doi.org\/10.3389\/fimmu.2024.1339757.","journal-title":"Front Immunol"},{"key":"4151_CR16","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/js9.0000000000002056","volume":"111","author":"Z Yu","year":"2025","unstructured":"Yu Z, et al. The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis. Int J Surg. 2025;111:1415\u201326. https:\/\/doi.org\/10.1097\/js9.0000000000002056.","journal-title":"Int J Surg"},{"key":"4151_CR17","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906.","journal-title":"Int J Surg"},{"key":"4151_CR18","doi-asserted-by":"publisher","unstructured":"Shea BJ et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj 358, j4008 (2017). https:\/\/doi.org\/10.1136\/bmj.j4008","DOI":"10.1136\/bmj.j4008"},{"key":"4151_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"4151_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16.","journal-title":"Trials"},{"key":"4151_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jclinepi.2018.08.022","volume":"105","author":"R Brignardello-Petersen","year":"2019","unstructured":"Brignardello-Petersen R, et al. GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks. J Clin Epidemiol. 2019;105:60\u20137. https:\/\/doi.org\/10.1016\/j.jclinepi.2018.08.022.","journal-title":"J Clin Epidemiol"},{"key":"4151_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Reviews. 2019. https:\/\/doi.org\/10.1002\/14651858.ED000142.","journal-title":"Cochrane Database Syst Reviews"},{"key":"4151_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1018598421607","volume":"7","author":"AP Dempster","year":"1997","unstructured":"Dempster AP. The direct use of likelihood for significance testing. Stat Comput. 1997;7:247\u201352. https:\/\/doi.org\/10.1023\/A:1018598421607.","journal-title":"Stat Comput"},{"key":"4151_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jclinepi.2016.02.016","volume":"76","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Straus SE, Fyraridis A, Tricco AC. The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes. J Clin Epidemiol. 2016;76:193\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.02.016.","journal-title":"J Clin Epidemiol"},{"key":"4151_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang YK, et al. Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdn717.","journal-title":"Ann Oncol"},{"key":"4151_CR26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ejso.2010.06.012","volume":"36","author":"M Imano","year":"2010","unstructured":"Imano M, et al. Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer. Eur J Surg Oncol. 2010;36:963\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2010.06.012.","journal-title":"Eur J Surg Oncol"},{"key":"4151_CR27","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","volume":"28","author":"C Schuhmacher","year":"2010","unstructured":"Schuhmacher C, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol. 2010;28:5210\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.26.6114.","journal-title":"J Clin Oncol"},{"key":"4151_CR28","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17:1697\u2013708. https:\/\/doi.org\/10.1016\/S1470-2045(16)30531-9.","journal-title":"Lancet Oncol"},{"key":"4151_CR29","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/annonc\/mdv620","volume":"27","author":"N Fazio","year":"2016","unstructured":"Fazio N, et al. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43\/99 phase III trial. Annals Oncology: Official J Eur Soc Med Oncol. 2016;27:668\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdv620.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"4151_CR30","doi-asserted-by":"publisher","unstructured":"Stahl M et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. European journal of cancer (Oxford, England: 1990) 81, 183-190 (2017). https:\/\/doi.org\/10.1016\/j.ejca.2017.04.027","DOI":"10.1016\/j.ejca.2017.04.027"},{"key":"4151_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1691\/ph.2017.6865","volume":"72","author":"Q Zhao","year":"2017","unstructured":"Zhao Q, et al. Short-term curative effect of S-1 plus oxaliplatin as perioperative chemo-therapy for locally advanced gastric cancer: a prospective comparison study. Pharmazie. 2017;72:236\u201340. https:\/\/doi.org\/10.1691\/ph.2017.6865.","journal-title":"Pharmazie"},{"key":"4151_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.21147\/j.issn.1000-9604.2018.05.05","volume":"30","author":"K Xue","year":"2018","unstructured":"Xue K, et al. Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial. Chin J Cancer Res. 2018;30:516\u2013. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2018.05.05.","journal-title":"Chin J Cancer Res"},{"key":"4151_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/ags3.12352","volume":"4","author":"T Hayashi","year":"2020","unstructured":"Hayashi T, et al. Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin\/S-1 and docetaxel\/cisplatin\/S-1 as neoadjuvant chemotherapy for advanced gastric cancer. Annals Gastroenterological Surg. 2020;4:540\u20138. https:\/\/doi.org\/10.1002\/ags3.12352.","journal-title":"Annals Gastroenterological Surg"},{"key":"4151_CR34","doi-asserted-by":"publisher","unstructured":"Sah BK, et al. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020;11. https:\/\/doi.org\/10.1038\/s41467-020-19965-6.","DOI":"10.1038\/s41467-020-19965-6"},{"key":"4151_CR35","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1002\/cam4.3224","volume":"9","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, et al. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: a multicenter randomized clinical trial. Cancer Med. 2020;9:5731\u201345. https:\/\/doi.org\/10.1002\/cam4.3224.","journal-title":"Cancer Med"},{"key":"4151_CR36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","volume":"24","author":"Y Iwasaki","year":"2021","unstructured":"Iwasaki Y, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24:492\u2013502. https:\/\/doi.org\/10.1007\/s10120-020-01136-7.","journal-title":"Gastric Cancer"},{"key":"4151_CR37","doi-asserted-by":"publisher","unstructured":"Tian Y, et al. Long-Term efficacy of neoadjuvant concurrent chemoradiotherapy for potentially resectable advanced Siewert type II and III adenocarcinomas of the esophagogastric junction. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.756440.","DOI":"10.3389\/fonc.2021.756440"},{"key":"4151_CR38","doi-asserted-by":"publisher","unstructured":"Tian Y, et al. Efficacy of neoadjuvant chemotherapy DOX and XELOX regimens for patients with resectable gastric or gastroesophageal junction adenocarcinoma. Gastroenterol Res Pract. 2021;2021. https:\/\/doi.org\/10.1155\/2021\/5590626.","DOI":"10.1155\/2021\/5590626"},{"key":"4151_CR39","doi-asserted-by":"publisher","unstructured":"Wang FL, et al. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study. Br J Radiol. 2021;94. https:\/\/doi.org\/10.1259\/bjr.20201088.","DOI":"10.1259\/bjr.20201088"},{"key":"4151_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12669\/pjms.37.7.4265","volume":"37","author":"PZ Zhou","year":"2021","unstructured":"Zhou PZ, Gao L, Wu W, Hao YX. Clinical effects of apatinib combined with Dos neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for Lagc. Pakistan J Med Sci. 2021;37:1\u20136. https:\/\/doi.org\/10.12669\/pjms.37.7.4265.","journal-title":"Pakistan J Med Sci"},{"key":"4151_CR41","doi-asserted-by":"publisher","unstructured":"Wang X, et al. Preoperative concurrent chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: phase II randomized study. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.870741.","DOI":"10.3389\/fonc.2022.870741"},{"key":"4151_CR42","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1097\/js9.0000000000000692","volume":"109","author":"Y Tian","year":"2023","unstructured":"Tian Y, et al. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. Int J Surg. 2023;109:4000\u20138. https:\/\/doi.org\/10.1097\/js9.0000000000000692.","journal-title":"Int J Surg"},{"key":"4151_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10120-024-01471-z","volume":"27","author":"ZC Jiang","year":"2024","unstructured":"Jiang ZC, et al. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial. Gastric Cancer. 2024;27:571\u20139. https:\/\/doi.org\/10.1007\/s10120-024-01471-z.","journal-title":"Gastric Cancer"},{"key":"4151_CR44","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.23.02167","volume":"42","author":"YK Kang","year":"2024","unstructured":"Kang YK, et al. Neoadjuvant Docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY. J Clin Oncol. 2024;42:2961\u20135. https:\/\/doi.org\/10.1200\/JCO.23.02167.","journal-title":"J Clin Oncol"},{"key":"4151_CR45","doi-asserted-by":"publisher","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","volume":"34","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, et al. LBA73 pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): interim results of the global, phase III MATTERHORN study. Ann Oncol. 2023;34:S1315\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.074.","journal-title":"Ann Oncol"},{"key":"4151_CR46","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.annonc.2023.09.1425","volume":"34","author":"C Li","year":"2023","unstructured":"Li C, et al. Perioperative camrelizumab (C) combined with Rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase III trial (DRAGON IV). Ann Oncol. 2023;34:852. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1425.","journal-title":"Ann Oncol"},{"key":"4151_CR47","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.62347\/eckt5511","volume":"15","author":"L Chi","year":"2025","unstructured":"Chi L, et al. Comparative effectiveness of perioperative strategies for resectable gastric and gastroesophageal junction cancer: a bayesian network meta-analysis. Am J Cancer Res. 2025;15:3781\u201394. https:\/\/doi.org\/10.62347\/eckt5511.","journal-title":"Am J Cancer Res"},{"key":"4151_CR48","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/s1470-2045(25)00286-4","volume":"26","author":"F Tian","year":"2025","unstructured":"Tian F, et al. Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial. Lancet Oncol. 2025;26:1043\u201354. https:\/\/doi.org\/10.1016\/s1470-2045(25)00286-4.","journal-title":"Lancet Oncol"},{"key":"4151_CR49","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijrobp.2025.04.020","volume":"123","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Neoadjuvant immunochemoradiation therapy versus chemoradiation therapy in esophageal cancer: A systematic review and Meta-Analysis of reconstructed individual patient data. Int J Radiat Oncol Biol Phys. 2025;123:483\u201394. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.04.020.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4151_CR50","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s10120-022-01314-9","volume":"25","author":"G Grizzi","year":"2022","unstructured":"Grizzi G, et al. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. Gastric Cancer. 2022;25:982\u20137. https:\/\/doi.org\/10.1007\/s10120-022-01314-9.","journal-title":"Gastric Cancer"},{"key":"4151_CR51","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393:217\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2503701.","journal-title":"N Engl J Med"},{"key":"4151_CR52","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/jco.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, et al. Double-Blind, Placebo-Controlled phase III trial of apatinib in patients with Chemotherapy-Refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncology: Official J Am Soc Clin Oncol. 2016;34:1448\u201354. https:\/\/doi.org\/10.1200\/jco.2015.63.5995. Randomized.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4151_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrclinonc.2016.53","volume":"13","author":"T Aoyama","year":"2016","unstructured":"Aoyama T, Yoshikawa T. Targeted therapy: Apatinib - new third-line option for refractory gastric or GEJ cancer. Nat Rev Clin Oncol. 2016;13:268\u201370. https:\/\/doi.org\/10.1038\/nrclinonc.2016.53.","journal-title":"Nat Rev Clin Oncol"},{"key":"4151_CR54","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10120-024-01484-8","volume":"27","author":"HD Kim","year":"2024","unstructured":"Kim HD, Ryu MH, Kang YK. Adjuvant treatment for locally advanced gastric cancer: an Asian perspective. Gastric Cancer. 2024;27:439\u201350. https:\/\/doi.org\/10.1007\/s10120-024-01484-8.","journal-title":"Gastric Cancer"},{"key":"4151_CR55","doi-asserted-by":"publisher","unstructured":"Lin JX et al. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial. JAMA network open 4, e2116240 (2021). https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.16240","DOI":"10.1001\/jamanetworkopen.2021.16240"},{"key":"4151_CR56","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/jco.24.00795","volume":"43","author":"C Li","year":"2025","unstructured":"Li C, et al. Pathologic response of phase III study: perioperative camrelizumab plus Rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J Clin Oncology: Official J Am Soc Clin Oncol. 2025;43:464\u201374. https:\/\/doi.org\/10.1200\/jco.24.00795.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4151_CR57","doi-asserted-by":"publisher","unstructured":"Huang D, Sun F, Ke L, Li S. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2024;138. https:\/\/doi.org\/10.1016\/j.intimp.2024.112576.","DOI":"10.1016\/j.intimp.2024.112576"},{"key":"4151_CR58","doi-asserted-by":"publisher","first-page":"e0189294","DOI":"10.1371\/journal.pone.0189294","volume":"13","author":"Z Li","year":"2018","unstructured":"Li Z, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PLoS ONE. 2018;13:e0189294. https:\/\/doi.org\/10.1371\/journal.pone.0189294.","journal-title":"PLoS ONE"},{"key":"4151_CR59","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1245\/s10434-018-07147-0","volume":"26","author":"T Wan","year":"2019","unstructured":"Wan T, et al. The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and Meta-Analysis of 21 studies. Ann Surg Oncol. 2019;26:1412\u201320. https:\/\/doi.org\/10.1245\/s10434-018-07147-0.","journal-title":"Ann Surg Oncol"},{"key":"4151_CR60","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.ejso.2020.12.010","volume":"47","author":"M Hayashi","year":"2021","unstructured":"Hayashi M, Fujita T, Matsushita H. Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric\/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2021;47:1996\u20132003. https:\/\/doi.org\/10.1016\/j.ejso.2020.12.010.","journal-title":"Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"key":"4151_CR61","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.ejso.2017.03.001","volume":"43","author":"G Tomasello","year":"2017","unstructured":"Tomasello G, et al. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2017;43:1607\u201316. https:\/\/doi.org\/10.1016\/j.ejso.2017.03.001.","journal-title":"Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"key":"4151_CR62","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/jco-25-00486","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara K, et al. Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the Randomized, phase III KEYNOTE-585 study. J Clin Oncology: Official J Am Soc Clin Oncol. 2025;43:3152\u20139. https:\/\/doi.org\/10.1200\/jco-25-00486.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04151-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:42:11Z","timestamp":1781624531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04151-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4151"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04151-z","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}